Source: International Congress 2017 – Current challenges in COPD evaluation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Ali Abo E-Magd (Tanta, Egypt). Soluble urokinase-type plasminogen activator receptor in monitoring of treatment response in acute exacerbation of chronic obstructive pulmonary disease. 405

Member's Comments

No comment yet.

Related content which might interest you: Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015 Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD Source: International Congress 2018 – New predictors of morbidity and mortality in COPD Year: 2018 Half - dose of recombinant tissue-type plasminogen activator in the treatment of acute pulmonary embolism: long term outcomes Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism Year: 2017 Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma Source: Eur Respir J 2016; 47:1568-1571 Year: 2016 The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017 Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung Year: 2010 Soluble urokinase plasminogen activator receptor (suPAR) is associated with COPD readmission and mortality Source: International Congress 2019 – Long-term lung function: from early birth to adulthood Year: 2019 Upregulation of the gene encoding the urokinase-type plasminogen activator (uPA) in respiratory muscles of COPD patients Source: Annual Congress 2004 - Skeletal muscle in respiratory disease Year: 2004 Recombinant thrombomodulin improves survival in acute exacerbation of idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Prognostic value of urokinase plasminogen activator receptor (uPAR) and neutrophil CD64 expression in acute respiratory distress syndrome patients Source: Annual Congress 2013 –Acute respiratory failure, ARDS and severe COPD exacerbations Year: 2013 Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014 Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia Source: ERJ Open Res, 5 (1) 00212-2018; 10.1183/23120541.00212-2018 Year: 2019 Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells Source: Eur Respir J 2007; 30: Suppl. 51, 143s Year: 2007 Tumor-associated antigens in acute exacerbation of idiopathic pulmonary fibrosis: Associations with disease activity Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 suppresses allergic asthma in a murine model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 LATE-BREAKING ABSTRACT: Molecular mechanisms of plasminogen activator inhibitor-1 elevation in COPD sputum Source: Annual Congress 2012 - Cell biology and inflammatory gene expression in chronic lung disease Year: 2012 SERPINE1 -675 4G/5G polymorphism is associated with asthma severity and inhaled corticosteroid response Source: Eur Respir J 2011; 38: 1036-1043 Year: 2011 Relationship between circulating thrombomodulin levels and latent progression of atherosclerosis in patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008 Enhanced expression of IL-18 receptor but not soluble form of IL18R in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011